Jiangxi Institute of Biological Products

Jiangxi Institute of Biological Products (Ticker: 6915 HK) develops, manufactures and sells human tetanus antitoxin products, antibody-based treatments used after possible exposure to tetanus. The treatment uses antibodies to neutralize the toxin that causes tetanus. The company produces antiserum in vial and ampoule preparations and markets its products in China, the Philippines, Egypt and other countries.

The scheduled listing date on Hong Kong Stock Exchange was June 30, 2026. The proposed offering comprises 36,230,000 shares at an indicative price range of HKD 9.33–13.06 per share. At the indicative range midpoint, the base offering would represent HKD 405.59 million, approximately $51.68 million in gross proceeds, excluding any unexercised over-allotment.